2013年,是一个不平凡的年份。从最先的PM2.5,到现在的H7N9……众多的公共卫生事件导致医药板块股价大涨;但这并不意味着海归已经能在国内医药行业大展拳脚。国内经济发展的良好势头,为医药界海归人才回国创业提供了难得的机遇。然而,面对国内医药研发、生产取得的成就以及存在的不足,独具优势的业内海归仍然心存观望,对他们来说“备好嫁妆才能不愁嫁”。 2013 is an extraordinary year. From the first PM2.5, to now H7N9 ... ... a large number of public health events led to share price rise in the pharmaceutical sector; But this does not mean that returnees have been able to flex its muscles in the domestic pharmaceutical industry. The good momentum of the domestic economic development provides a rare opportunity for the pharmaceutical industry to return to its hometown for returnees. However, in the face of the domestic pharmaceutical research and development, production achievements and shortcomings, the unique advantages of the industry are still waiting to see the returnees, for them ".